Check for updates

OPEN ACCESS

APPROVED BY Frontiers Editorial Office, Frontiers Media SA, Switzerland

*CORRESPONDENCE Victoria A. Jennings Vicki.jennings@york.ac.uk

[†]PRESENT ADDRESS

Victoria A. Jennings, Jack Birch Unit for Molecular Carcinogenesis, Department of Biology & York Biomedical Research Institute, University of York, York, United Kingdom

[‡]These authors share last authorship

RECEIVED 27 March 2025 ACCEPTED 03 April 2025 PUBLISHED 22 April 2025

CITATION

Jennings VA, Rumbold-Hall R, Migneco G, Barr T, Reilly K, Ingram N, Hilare IS, Heaton S, Alzamel N, Jackson D, Ralph C, Banerjee S, McNeish I, Bell JC, Melcher AA, Ilkow C, Cook GP and Errington-Mais F (2025) Corrigendum: Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprogramming of the tumour microenvironment. *Front. Immunol.* 16:1601201. doi: 10.3389/fimmu.2025.1601201

COPYRIGHT

© 2025 Jennings, Rumbold-Hall, Migneco, Barr, Reilly, Ingram, Hilare, Heaton, Alzamel, Jackson, Ralph, Banerjee, McNeish, Bell, Melcher, Ilkow, Cook and Errington-Mais. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprogramming of the tumour microenvironment

Victoria A. Jennings^{1*†}, Reah Rumbold-Hall¹, Gemma Migneco¹, Tyler Barr¹, Katrina Reilly¹, Nicola Ingram¹, Isabelle St Hilare², Samuel Heaton¹, Noura Alzamel¹, David Jackson³, Christy Ralph³, Susan Banerjee⁴, Iain McNeish⁵, John C. Bell², Alan A. Melcher⁶, Carolina Ilkow², Graham P. Cook^{1†} and Fiona Errington-Mais^{1†}

¹Leeds Institute of Medical Research, School of Medicine, University of Leeds, St. James University Hospital, Leeds, United Kingdom, ²Center for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada, ³Leeds Cancer Centre, St James's Hospital, Leeds, United Kingdom, ⁴The Royal Marsden Hospital, Fulham Road, London, United Kingdom, ⁵Department of Cancer and Surgery, Imperial College London, London, United Kingdom, ⁶The Institute of Cancer Research, Divisions of Radiotherapy and Imaging and Breast Cancer Research, Chester Beatty Laboratories, London, United Kingdom

KEYWORDS

oncolytic virus, miRNA, tumour associated macrophage, tumour microenvironment, anti-tumour immunity

A Corrigendum on

Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprogramming of the tumour microenvironment

By Jennings VA, Rumbold-Hall R, Migneco G, Barr T, Reilly K, Ingram N, St Hilare I, Heaton S, Alzamel N, Jackson D, Ralph C, Banerjee S, McNeish I, Bell JC, Melcher AA, Ilkow C, Cook GP and Errington-Mais F (2024). *Front. Immunol.* 15:1500570. doi: 10.3389/fimmu.2024.1500570

In the published article, there was an error in the article title. Instead of "Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprograming of the tumour microenvironment", it should be "Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprogramming of the tumour microenvironment".

In the published article, there was an error in the **Funding** statement. Several funders were omitted from the original statement. The correct **Funding** statement appears below.

"The authors declare that financial support was received for the research, authorship, and/or publication of this article. Ovarian Cancer Action funded Victoria Jennings, Reah Rumbold-Hall and the costs required to undertake this study. Alan Melcher was supported by CRUK (Programme grant CRM183X), Tyler Barr was supported by the Myrovlytis Trust and by an MRC/NIHR Cancer Research Transatlantic Development and Skills Enhancement Award (NIHR304246), Samuel Heaton by an MRC Discovery Medicine North (DiMeN) studentship (MR/N013840/1) and Noura Alzamel by a scholarship from

Kuwait University. Nicola Ingram is supported in part by the National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre (BRC) (NIHR213331). Other authors were supported by their respective institutions. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care, or any other funders of this work."

In the published article, there was an error in the **Acknowledgements**. Funders others than Ovarian Cancer Action were omitted from the original statement. The correct statement appears below.

"The authors would like to extend their sincere gratitude to Ovarian Cancer Action for their generous funding and support, which made this research possible. Their commitment to advancing ovarian cancer research, has been instrumental in enabling us to carry out this study. We thank the other organisations who supported the study and thank our colleagues Robert Salmond and Sandra Bell for the kind gift of materials and for their scientific input into this study."

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.